Remix Therapeutics is using the clinical success of its first drug (targeting MYB) to validate its entire RNA modulation platform. This initial proof-of-concept provides strong rationale and investor confidence to pursue even more challenging and significant oncogenes like MYC, one of oncology's most sought-after targets.

Instead of a traditional IPO, Candid Therapeutics secured a NASDAQ listing and a massive capital infusion by merging with RallyBio. This reverse merger, coupled with a concurrent private investment, provides nearly $700 million in cash to fund operations through 2030, demonstrating a powerful alternative financing path to public markets.

The recent biotech market downturn raised the bar for going public. Unlike the 2020-2021 period where preclinical companies IPO'd, today's successful offerings are from companies with mid-to-late-stage clinical programs. This de-risked profile is necessary to attract both specialist and crucial generalist investors back to the sector.

After Actuate Therapeutics released positive early trial data for pediatric cancers, leading international research groups initiated contact. They not only wanted to help develop the drug but had already independently tested the molecule, demonstrating how powerful data can attract inbound, high-caliber partnership opportunities.

Successful clinical data is being immediately rewarded with significant capital, indicating a robust funding market. Xenon and Dianthus both raised over $700 million following positive trial results, demonstrating strong investor appetite to fund de-risked assets and reward companies that deliver on clinical promises.

When traditional venture funding dried up for Madrigal Pharmaceuticals, they found an unconventional path to capital and a public listing. They pursued a reverse merger with Cinta, a public company that had recently failed a Phase 3 trial and was seeking an exit. This "bake off" victory secured Madrigal $41 million.

Biotech companies are increasingly favoring reverse mergers over traditional IPOs. The process allows for confidential diligence with select funds, is faster, and sidesteps market volatility like election uncertainty. The previous stigma is fading as the quality of investor syndicates remains high.

Remix Therapeutics is going public by merging with an existing public company, Passage Bio, and raising a concurrent $100M financing. This reverse merger strategy provides a faster and potentially less volatile route to the stock exchange compared to a traditional IPO, allowing them to quickly capitalize on positive clinical momentum.

The closed IPO window forced many private biotech companies to achieve significant clinical milestones, like Phase 2 proof-of-concept, while still private. This has created an unusual cohort of well-seasoned, de-risked companies with attractive valuations, poised to be highly appealing to public investors.